Rheumatology News

Increasing the dosage of secukinumab failed to improve ankylosing spondylitis outcomes among patients who initially demonstrated an inadequate treatment response, according to data published in Rheumatology.

Rates of osteoporosis and osteoporotic fractures have fallen significantly among patients with rheumatoid arthritis over the past 24 years, according to a single-center study published in RMD Open.

Radiofrequency ablation and transcatheter arterial embolization — both minimally invasive procedures — can improve pain and function in patients with osteoarthritis or chronic sacroiliac pain of degenerative origin, according to data.

U.S. adults with higher triglyceride glycemic index scores demonstrate a greater likelihood of developing gout, according to data published in the Journal of Health, Population and Nutrition.

Patients with systemic lupus erythematosus who are positive for anti-Ro60 or anti-Ro52 antibodies may face higher disease activity and more intensive treatment needs, according to data published in Rheumatology.

Intravenous golimumab yielded a durable clinical response through 116 weeks, with a stable safety profile, in polyarticular-course juvenile idiopathic arthritis, according to data published in The Journal of Rheumatology.

Switching from a TNF inhibitor to upadacitinib leads to significantly better outcomes in rheumatoid arthritis vs. cycling TNF inhibitors or switching to another mechanism of action, according to data published in Advances in Therapy.

Protecting immunocompromised individuals from infections like herpes zoster is an ongoing challenge for every rheumatologist.

The FDA has granted orphan drug designation to AISA-021, a fourth-generation calcium channel blocker, for the treatment of systemic sclerosis, according to a press release from Aisa Pharma.